The IT services firm strengthens its collaboration with Google Cloud to help enterprises move AI from pilot projects to production systems
Updated
February 18, 2026 8:11 PM
Google Cloud building. PHOTO: ADOBE STOCK
Enterprise interest in AI has moved quickly from experimentation to execution. Many organizations have tested generative tools, but turning those tools into systems that can run inside daily operations remains a separate challenge. Cognizant, an IT services firm, is expanding its partnership with Google Cloud to help enterprises move from AI pilots to fully deployed, production-ready systems.
Cognizant and Google Cloud are deepening their collaboration around Google’s Gemini Enterprise and Google Workspace. Cognizant is deploying these tools across its own workforce first, using them to support internal productivity and collaboration. The idea is simple: test and refine the systems internally, then package similar capabilities for clients.
The focus of the partnership is what Cognizant calls “agentic AI.” In practical terms, this refers to AI systems that can plan, act and complete tasks with limited human input. Instead of generating isolated outputs, these systems are designed to fit into business workflows and carry out structured tasks.
To make that workable at scale, Cognizant is building delivery infrastructure around the technology. The company is setting up a dedicated Gemini Enterprise Center of Excellence and formalizing an Agent Development Lifecycle. This framework covers the full process, from early design and blueprinting to validation and production rollout. The aim is to give enterprises a clearer path from the AI concept to a deployed system.
Cognizant also plans to introduce a bundled productivity offering that combines Gemini Enterprise with Google Workspace. The targeted use cases are operational rather than experimental. These include collaborative content creation, supplier communications and other workflow-heavy processes that can be standardized and automated.
Beyond productivity tools, Cognizant is integrating Gemini into its broader service platforms. Through Cognizant Ignition, enabled by Gemini, the company supports early-stage discovery and prototyping while helping clients strengthen their data foundations. Its Agent Foundry platform provides pre-configured and no-code capabilities for specific use cases such as AI-powered contact centers and intelligent order management. These tools are designed to reduce the amount of custom development required for each deployment.
Scaling is another element of the strategy. Cognizant, a multi-year Google Cloud Data Partner of the Year award winner, says it will rely on a global network of Gemini-trained specialists to deliver these systems. The company is also expanding work tied to Google Distributed Cloud and showcasing capabilities through its Google Experience Zones and Gen AI Studios.
For Google Cloud, the partnership reinforces its enterprise AI ecosystem. Cloud providers can offer models and infrastructure, but enterprise adoption often depends on service partners that can integrate tools into existing systems and manage ongoing operations. By aligning closely with Cognizant, Google strengthens its ability to move Gemini from platform capability to production deployment.
The announcement does not introduce a new AI model. Instead, it reflects a shift in emphasis. The core question is no longer whether AI tools exist, but how they are implemented, governed and scaled across large organizations. Cognizant’s expanded role suggests that execution frameworks, internal deployment and structured delivery models are becoming central to how enterprises approach AI.
In that sense, the partnership is less about new technology and more about operational maturity. It highlights how AI is moving from isolated pilots to managed systems embedded in business processes — a transition that will likely define the next phase of enterprise adoption.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.